A Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/r With or Without Dasabuvir and With or Without Ribavirin in Chronic Hepatitis C Virus Genotype 1 or 4 Infected Adults With Successfully Treated Early Stage Hepatocellular Carcinoma

NCT02504099 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

3

Enrollment

INDUSTRY

Sponsor class

Stopped Study stopped due to low enrollment

Conditions

Chronic Hepatitis C Infection

Interventions

DRUG: ombitasvir/paritaprevir/ritonavir and dasabuvir
DRUG: ombitasvir/paritaprevir/ritonavir
DRUG: ribavirin

Sponsor

AbbVie